Opdivo® (nivolumab) is registered for therapy of a cancer of a stomach

Company Bristol-Myers Squibb registered to Russian Federation the new indication for the immunooncological preparation Opdivo® (nivolumab).soglasno the updated instruction on application the preparation Opdivo® (nivolumab) Company Bristol-Myers Squibb registered to Russian Federation the new indication for the immunooncological preparation Opdivo® (nivolumab).soglasno the updated instruction on application the preparation Opdivo® (nivolumab)...